JNJ

226.97

+0.64%↑

ABT

93.9

+1.65%↑

MDT

81.82

-1.36%↓

115.47

-0.09%↓

VEEV

160.15

-0.9%↓

JNJ

226.97

+0.64%↑

ABT

93.9

+1.65%↑

MDT

81.82

-1.36%↓

115.47

-0.09%↓

VEEV

160.15

-0.9%↓

JNJ

226.97

+0.64%↑

ABT

93.9

+1.65%↑

MDT

81.82

-1.36%↓

115.47

-0.09%↓

VEEV

160.15

-0.9%↓

JNJ

226.97

+0.64%↑

ABT

93.9

+1.65%↑

MDT

81.82

-1.36%↓

115.47

-0.09%↓

VEEV

160.15

-0.9%↓

JNJ

226.97

+0.64%↑

ABT

93.9

+1.65%↑

MDT

81.82

-1.36%↓

115.47

-0.09%↓

VEEV

160.15

-0.9%↓

Home・Aandelen Lijst・Pulmatrix Inc

Pulmatrix Inc

Open

1.29 2.38

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.28

Max

1.33

Belangrijke statistieken
By Trading Economics
Inkomsten	-51K -928K
EPS	-0.254
Werknemers	2
EBITDA	-51K -928K

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-6.5M 4.9M
Vorige openingsprijs	-1.09
Vorige sluitingsprijs	1.29

Pulmatrix Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

27 apr 2026, 23:15 UTC

Belangrijke Nieuwsgebeurtenissen

U.K. Consumers Pay Less But Full Impact of Mideast War to Be Seen

27 apr 2026, 23:08 UTC

Winsten

Belangrijke Marktbewegers

LendingClub Shares Gain on 1Q Profit, Revenue Beat

27 apr 2026, 23:58 UTC

Winsten

Samsung SDI 1Q Net Profit Beat FactSet-Compiled Consensus

27 apr 2026, 23:58 UTC

Winsten

Samsung SDI 1Q Net KRW56.10B Vs. Loss KRW216.00B >006400.SE

27 apr 2026, 23:56 UTC

Winsten

Samsung SDI 1Q Oper Loss KRW155.60B Vs. Loss KRW434.10B >006400.SE

27 apr 2026, 23:56 UTC

Winsten

Samsung SDI 1Q Rev KRW3.576T Vs. KRW3.177T >006400.SE

27 apr 2026, 23:48 UTC

Marktinformatie

Nikkei May Remain Rangebound Amid Uncertainty Over Iran Conflict -- Market Talk

27 apr 2026, 23:42 UTC

Marktinformatie

Australian Consumer Confidence Making a Slow Come Back -- Market Talk

27 apr 2026, 23:34 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Gold Edges Higher as Investors Assess Iran's Proposal to U.S. -- Market Talk

27 apr 2026, 23:30 UTC

Marktinformatie

Australia's NDIS Could Lose 'Social Licence' If Not Reined In -- Market Talk

27 apr 2026, 23:08 UTC

Marktinformatie

Polymetals's Revenue Outlook 'Extraordinary' for a Small-Cap Stock -- Market Talk

27 apr 2026, 23:02 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

27 apr 2026, 23:02 UTC

Marktinformatie

Warsh Will Probably Lean a Bit More Dovish Than Powell -- Market Talk

27 apr 2026, 22:42 UTC

Marktinformatie

BOJ Expected to Keep Rates On Hold; Guidance to Skew Hawkish -- Market Talk

27 apr 2026, 22:10 UTC

Winsten

Haier Smart Home: Results Also Weighed by Weak Demand in China-U.S. Markets >600690.SH

27 apr 2026, 22:09 UTC

Winsten

Haier Smart Home: Increase in Tariff Costs, Extreme Weather Conditions Hurt Results >600690.SH

27 apr 2026, 22:09 UTC

Winsten

Haier Smart Home 1Q Net CNY4.65B Vs. Net CNY5.49B >600690.SH

27 apr 2026, 22:09 UTC

Winsten

Haier Smart Home 1Q Rev CNY73.69B Vs. CNY79.12B >600690.SH

27 apr 2026, 21:56 UTC

Winsten

Tsingtao Brewery: Cost Controls Among Factors Supporting Results >0168.HK

27 apr 2026, 21:55 UTC

Winsten

Tsingtao Brewery 1Q Net CNY1.80B Vs. Net CNY1.71B >0168.HK

27 apr 2026, 21:55 UTC

Winsten

Tsingtao Brewery 1Q Rev CNY10.29B Vs. CNY10.45B >0168.HK

27 apr 2026, 21:44 UTC

Winsten

Tianqi Lithium: Higher Demand for Products From EV Sector Also Boosted Financial Performance >002466.SZ

27 apr 2026, 21:43 UTC

Winsten

Tianqi Lithium: Increase in Average Selling Prices of Major Lithium Products Supported Results >002466.SZ

27 apr 2026, 21:41 UTC

Winsten

Tianqi Lithium 1Q Rev CNY5.13B Vs. CNY2.58B >002466.SZ

27 apr 2026, 21:41 UTC

Winsten

Tianqi Lithium 1Q Net CNY1.88B Vs. Net CNY104.27M >002466.SZ

27 apr 2026, 20:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

27 apr 2026, 20:50 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Basic Materials Roundup: Market Talk

27 apr 2026, 20:50 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Financial Services Roundup: Market Talk

27 apr 2026, 20:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

27 apr 2026, 20:39 UTC

Winsten

Nucor: Operating Segments Earnings Growth Driven by Trade Policies That Continue to Reduce Flood of Unfairly Traded Imports Into U.S. >NUE

Peer Vergelijking

Prijswijziging

Pulmatrix Inc Prognose

Beoordelingsconsensus

By TipRanks

0 ratings

Buy

Hold

Sell

Gebaseerd op 0 analisten die aandelenratings hebben gegeven aan Pulmatrix Inc - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Pulmatrix Inc

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.